LymphedemaV1, PascalFrancis, Corpus, bibRecord, 000618

Lymphedema after complete axillary node dissection for melanoma: Assessment using a new, objective definition

Identifieur interne : 000618 ( PascalFrancis/Corpus ); précédent : 000617; suivant : 000619

Lymphedema after complete axillary node dissection for melanoma: Assessment using a new, objective definition

Auteurs : Emma C. Starritt ; David Joseph ; J. Gregory Mckinnon ; SING KAI LO ; Johannes H. W. De Wilt ; John F. Thompson

Source :

Annals of surgery [ 0003-4932 ] ; 2004.

RBID : Pascal:04-0591759

Descripteurs français

Pascal (Inist)
- Lymphoedème, Complet, Ganglion axillaire, Mélanome malin, Dissection, Définition, Médecine, Chirurgie, Traitement.

English descriptors

KwdEn :
- Axillary ganglion, Complete, Definition, Dissection, Lymphedema, Malignant melanoma, Medicine, Surgery, Treatment.

Abstract

Objectives: The objectives of this study were to define appropriate criteria for assessing the presence of lymphedema, and to report the prevalence and risk factors for development of upper limb lymphedema after level I-III axillary dissection for melanoma. Background Data: The lack of a consistent and reliable objective definition for lymphedema remains a significant barrier to appreciating its prevalence after axillary dissection for melanoma (or breast carcinoma). Methods: Lymphedema was assessed in 107 patients (82 male, 25 female) who had previously undergone complete level I-III axillary dissection. Of the 107 patients, 17 had also received postoperative axillary radiotherapy. Arm volume was measured using a water displacement technique. Change in volume of the arm on the side of the dissection was referenced to the volume of the other (control) arm. Volume measurements were corrected for the effect of handedness using corrections derived from a control group. Classification and regression tree (CART) analysis was used to determine a threshold fractional arm volume increase above which volume changes were considered to indicate lymphedema. Results: Based on the CART analysis results, lymphedema was defined as an increase in arm volume greater than 16% of the volume of the control arm. Using this definition, lymphedema prevalence for patients in the present study was 10% after complete level I-III axillary dissection for melanoma and 53% after additional axillary radiotherapy. Radiotherapy and wound complications were independent risk factors for the development of lymphedema. Conclusions: A suggested objective definition for arm lymphedema after axillary dissection is an arm volume increase of greater than 16% of the volume of the control arm.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0003-4932`
A02	`01`			`@0 ANSUA5`
A03		`1`		`@0 Ann. surg.`
A05				`@2 240`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Lymphedema after complete axillary node dissection for melanoma: Assessment using a new, objective definition`
A11	`01`	`1`		`@1 STARRITT (Emma C.)`
A11	`02`	`1`		`@1 JOSEPH (David)`
A11	`03`	`1`		`@1 MCKINNON (J. Gregory)`
A11	`04`	`1`		`@1 SING KAI LO`
A11	`05`	`1`		`@1 DE WILT (Johannes H. W.)`
A11	`06`	`1`		`@1 THOMPSON (John F.)`
A14	`01`			`@1 Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital @2 Camperdown @3 AUS @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Institute for International Health, University of Sydney @2 Newtown @3 AUS @Z 4 aut.`
A14	`03`			`@1 TDepartment of Surgery, University of Sydney @3 AUS @Z 6 aut.`
A20				`@1 866-874`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 2016 @5 354000120551830190`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 04-0591759`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Annals of surgery`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Objectives: The objectives of this study were to define appropriate criteria for assessing the presence of lymphedema, and to report the prevalence and risk factors for development of upper limb lymphedema after level I-III axillary dissection for melanoma. Background Data: The lack of a consistent and reliable objective definition for lymphedema remains a significant barrier to appreciating its prevalence after axillary dissection for melanoma (or breast carcinoma). Methods: Lymphedema was assessed in 107 patients (82 male, 25 female) who had previously undergone complete level I-III axillary dissection. Of the 107 patients, 17 had also received postoperative axillary radiotherapy. Arm volume was measured using a water displacement technique. Change in volume of the arm on the side of the dissection was referenced to the volume of the other (control) arm. Volume measurements were corrected for the effect of handedness using corrections derived from a control group. Classification and regression tree (CART) analysis was used to determine a threshold fractional arm volume increase above which volume changes were considered to indicate lymphedema. Results: Based on the CART analysis results, lymphedema was defined as an increase in arm volume greater than 16% of the volume of the control arm. Using this definition, lymphedema prevalence for patients in the present study was 10% after complete level I-III axillary dissection for melanoma and 53% after additional axillary radiotherapy. Radiotherapy and wound complications were independent risk factors for the development of lymphedema. Conclusions: A suggested objective definition for arm lymphedema after axillary dissection is an arm volume increase of greater than 16% of the volume of the control arm.
C02	`01`	`X`		`@0 002B01`
C02	`02`	`X`		`@0 002B12B04`
C03	`01`	`X`	`FRE`	`@0 Lymphoedème @5 01`
C03	`01`	`X`	`ENG`	`@0 Lymphedema @5 01`
C03	`01`	`X`	`SPA`	`@0 Linfedema @5 01`
C03	`02`	`X`	`FRE`	`@0 Complet @5 02`
C03	`02`	`X`	`ENG`	`@0 Complete @5 02`
C03	`02`	`X`	`SPA`	`@0 Completo @5 02`
C03	`03`	`X`	`FRE`	`@0 Ganglion axillaire @5 03`
C03	`03`	`X`	`ENG`	`@0 Axillary ganglion @5 03`
C03	`03`	`X`	`SPA`	`@0 Ganglio axilar @5 03`
C03	`04`	`X`	`FRE`	`@0 Mélanome malin @5 04`
C03	`04`	`X`	`ENG`	`@0 Malignant melanoma @5 04`
C03	`04`	`X`	`SPA`	`@0 Melanoma maligno @5 04`
C03	`05`	`X`	`FRE`	`@0 Dissection @5 05`
C03	`05`	`X`	`ENG`	`@0 Dissection @5 05`
C03	`05`	`X`	`SPA`	`@0 Disección @5 05`
C03	`06`	`X`	`FRE`	`@0 Définition @5 06`
C03	`06`	`X`	`ENG`	`@0 Definition @5 06`
C03	`06`	`X`	`SPA`	`@0 Definición @5 06`
C03	`07`	`X`	`FRE`	`@0 Médecine @5 08`
C03	`07`	`X`	`ENG`	`@0 Medicine @5 08`
C03	`07`	`X`	`SPA`	`@0 Medicina @5 08`
C03	`08`	`X`	`FRE`	`@0 Chirurgie @5 09`
C03	`08`	`X`	`ENG`	`@0 Surgery @5 09`
C03	`08`	`X`	`SPA`	`@0 Cirugía @5 09`
C03	`09`	`X`	`FRE`	`@0 Traitement @5 25`
C03	`09`	`X`	`ENG`	`@0 Treatment @5 25`
C03	`09`	`X`	`SPA`	`@0 Tratamiento @5 25`
C07	`01`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Lymphatique pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Linfático patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Tumeur maligne @5 39`
C07	`03`	`X`	`ENG`	`@0 Malignant tumor @5 39`
C07	`03`	`X`	`SPA`	`@0 Tumor maligno @5 39`
N21				`@1 341`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 04-0591759 INIST
ET :	Lymphedema after complete axillary node dissection for melanoma: Assessment using a new, objective definition
AU :	STARRITT (Emma C.); JOSEPH (David); MCKINNON (J. Gregory); SING KAI LO; DE WILT (Johannes H. W.); THOMPSON (John F.)
AF :	Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital/Camperdown/Australie (1 aut., 2 aut., 3 aut., 5 aut., 6 aut.); Institute for International Health, University of Sydney/Newtown/Australie (4 aut.); TDepartment of Surgery, University of Sydney/Australie (6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Annals of surgery; ISSN 0003-4932; Coden ANSUA5; Etats-Unis; Da. 2004; Vol. 240; No. 5; Pp. 866-874; Bibl. 25 ref.
LA :	Anglais
EA :	Objectives: The objectives of this study were to define appropriate criteria for assessing the presence of lymphedema, and to report the prevalence and risk factors for development of upper limb lymphedema after level I-III axillary dissection for melanoma. Background Data: The lack of a consistent and reliable objective definition for lymphedema remains a significant barrier to appreciating its prevalence after axillary dissection for melanoma (or breast carcinoma). Methods: Lymphedema was assessed in 107 patients (82 male, 25 female) who had previously undergone complete level I-III axillary dissection. Of the 107 patients, 17 had also received postoperative axillary radiotherapy. Arm volume was measured using a water displacement technique. Change in volume of the arm on the side of the dissection was referenced to the volume of the other (control) arm. Volume measurements were corrected for the effect of handedness using corrections derived from a control group. Classification and regression tree (CART) analysis was used to determine a threshold fractional arm volume increase above which volume changes were considered to indicate lymphedema. Results: Based on the CART analysis results, lymphedema was defined as an increase in arm volume greater than 16% of the volume of the control arm. Using this definition, lymphedema prevalence for patients in the present study was 10% after complete level I-III axillary dissection for melanoma and 53% after additional axillary radiotherapy. Radiotherapy and wound complications were independent risk factors for the development of lymphedema. Conclusions: A suggested objective definition for arm lymphedema after axillary dissection is an arm volume increase of greater than 16% of the volume of the control arm.
CC :	002B01; 002B12B04
FD :	Lymphoedème; Complet; Ganglion axillaire; Mélanome malin; Dissection; Définition; Médecine; Chirurgie; Traitement
FG :	Appareil circulatoire pathologie; Lymphatique pathologie; Tumeur maligne
ED :	Lymphedema; Complete; Axillary ganglion; Malignant melanoma; Dissection; Definition; Medicine; Surgery; Treatment
EG :	Cardiovascular disease; Lymphatic vessel disease; Malignant tumor
SD :	Linfedema; Completo; Ganglio axilar; Melanoma maligno; Disección; Definición; Medicina; Cirugía; Tratamiento
LO :	INIST-2016.354000120551830190
ID :	04-0591759

Links to Exploration step

Pascal:04-0591759

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Lymphedema after complete axillary node dissection for melanoma: Assessment using a new, objective definition</title>
<author><name sortKey="Starritt, Emma C" sort="Starritt, Emma C" uniqKey="Starritt E" first="Emma C." last="Starritt">Emma C. Starritt</name>
<affiliation><inist:fA14 i1="01"><s1>Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital</s1>
<s2>Camperdown</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Joseph, David" sort="Joseph, David" uniqKey="Joseph D" first="David" last="Joseph">David Joseph</name>
<affiliation><inist:fA14 i1="01"><s1>Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital</s1>
<s2>Camperdown</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mckinnon, J Gregory" sort="Mckinnon, J Gregory" uniqKey="Mckinnon J" first="J. Gregory" last="Mckinnon">J. Gregory Mckinnon</name>
<affiliation><inist:fA14 i1="01"><s1>Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital</s1>
<s2>Camperdown</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sing Kai Lo" sort="Sing Kai Lo" uniqKey="Sing Kai Lo" last="Sing Kai Lo">SING KAI LO</name>
<affiliation><inist:fA14 i1="02"><s1>Institute for International Health, University of Sydney</s1>
<s2>Newtown</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Wilt, Johannes H W" sort="De Wilt, Johannes H W" uniqKey="De Wilt J" first="Johannes H. W." last="De Wilt">Johannes H. W. De Wilt</name>
<affiliation><inist:fA14 i1="01"><s1>Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital</s1>
<s2>Camperdown</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thompson, John F" sort="Thompson, John F" uniqKey="Thompson J" first="John F." last="Thompson">John F. Thompson</name>
<affiliation><inist:fA14 i1="01"><s1>Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital</s1>
<s2>Camperdown</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>TDepartment of Surgery, University of Sydney</s1>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0591759</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0591759 INIST</idno>
<idno type="RBID">Pascal:04-0591759</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000618</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Lymphedema after complete axillary node dissection for melanoma: Assessment using a new, objective definition</title>
<author><name sortKey="Starritt, Emma C" sort="Starritt, Emma C" uniqKey="Starritt E" first="Emma C." last="Starritt">Emma C. Starritt</name>
<affiliation><inist:fA14 i1="01"><s1>Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital</s1>
<s2>Camperdown</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Joseph, David" sort="Joseph, David" uniqKey="Joseph D" first="David" last="Joseph">David Joseph</name>
<affiliation><inist:fA14 i1="01"><s1>Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital</s1>
<s2>Camperdown</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mckinnon, J Gregory" sort="Mckinnon, J Gregory" uniqKey="Mckinnon J" first="J. Gregory" last="Mckinnon">J. Gregory Mckinnon</name>
<affiliation><inist:fA14 i1="01"><s1>Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital</s1>
<s2>Camperdown</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sing Kai Lo" sort="Sing Kai Lo" uniqKey="Sing Kai Lo" last="Sing Kai Lo">SING KAI LO</name>
<affiliation><inist:fA14 i1="02"><s1>Institute for International Health, University of Sydney</s1>
<s2>Newtown</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Wilt, Johannes H W" sort="De Wilt, Johannes H W" uniqKey="De Wilt J" first="Johannes H. W." last="De Wilt">Johannes H. W. De Wilt</name>
<affiliation><inist:fA14 i1="01"><s1>Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital</s1>
<s2>Camperdown</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thompson, John F" sort="Thompson, John F" uniqKey="Thompson J" first="John F." last="Thompson">John F. Thompson</name>
<affiliation><inist:fA14 i1="01"><s1>Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital</s1>
<s2>Camperdown</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>TDepartment of Surgery, University of Sydney</s1>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of surgery</title>
<title level="j" type="abbreviated">Ann. surg.</title>
<idno type="ISSN">0003-4932</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of surgery</title>
<title level="j" type="abbreviated">Ann. surg.</title>
<idno type="ISSN">0003-4932</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Axillary ganglion</term>
<term>Complete</term>
<term>Definition</term>
<term>Dissection</term>
<term>Lymphedema</term>
<term>Malignant melanoma</term>
<term>Medicine</term>
<term>Surgery</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphoedème</term>
<term>Complet</term>
<term>Ganglion axillaire</term>
<term>Mélanome malin</term>
<term>Dissection</term>
<term>Définition</term>
<term>Médecine</term>
<term>Chirurgie</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objectives: The objectives of this study were to define appropriate criteria for assessing the presence of lymphedema, and to report the prevalence and risk factors for development of upper limb lymphedema after level I-III axillary dissection for melanoma. Background Data: The lack of a consistent and reliable objective definition for lymphedema remains a significant barrier to appreciating its prevalence after axillary dissection for melanoma (or breast carcinoma). Methods: Lymphedema was assessed in 107 patients (82 male, 25 female) who had previously undergone complete level I-III axillary dissection. Of the 107 patients, 17 had also received postoperative axillary radiotherapy. Arm volume was measured using a water displacement technique. Change in volume of the arm on the side of the dissection was referenced to the volume of the other (control) arm. Volume measurements were corrected for the effect of handedness using corrections derived from a control group. Classification and regression tree (CART) analysis was used to determine a threshold fractional arm volume increase above which volume changes were considered to indicate lymphedema. Results: Based on the CART analysis results, lymphedema was defined as an increase in arm volume greater than 16% of the volume of the control arm. Using this definition, lymphedema prevalence for patients in the present study was 10% after complete level I-III axillary dissection for melanoma and 53% after additional axillary radiotherapy. Radiotherapy and wound complications were independent risk factors for the development of lymphedema. Conclusions: A suggested objective definition for arm lymphedema after axillary dissection is an arm volume increase of greater than 16% of the volume of the control arm.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0003-4932</s0>
</fA01>
<fA02 i1="01"><s0>ANSUA5</s0>
</fA02>
<fA03 i2="1"><s0>Ann. surg.</s0>
</fA03>
<fA05><s2>240</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Lymphedema after complete axillary node dissection for melanoma: Assessment using a new, objective definition</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>STARRITT (Emma C.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JOSEPH (David)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MCKINNON (J. Gregory)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SING KAI LO</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DE WILT (Johannes H. W.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>THOMPSON (John F.)</s1>
</fA11>
<fA14 i1="01"><s1>Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital</s1>
<s2>Camperdown</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute for International Health, University of Sydney</s1>
<s2>Newtown</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>TDepartment of Surgery, University of Sydney</s1>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>866-874</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2016</s2>
<s5>354000120551830190</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0591759</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of surgery</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objectives: The objectives of this study were to define appropriate criteria for assessing the presence of lymphedema, and to report the prevalence and risk factors for development of upper limb lymphedema after level I-III axillary dissection for melanoma. Background Data: The lack of a consistent and reliable objective definition for lymphedema remains a significant barrier to appreciating its prevalence after axillary dissection for melanoma (or breast carcinoma). Methods: Lymphedema was assessed in 107 patients (82 male, 25 female) who had previously undergone complete level I-III axillary dissection. Of the 107 patients, 17 had also received postoperative axillary radiotherapy. Arm volume was measured using a water displacement technique. Change in volume of the arm on the side of the dissection was referenced to the volume of the other (control) arm. Volume measurements were corrected for the effect of handedness using corrections derived from a control group. Classification and regression tree (CART) analysis was used to determine a threshold fractional arm volume increase above which volume changes were considered to indicate lymphedema. Results: Based on the CART analysis results, lymphedema was defined as an increase in arm volume greater than 16% of the volume of the control arm. Using this definition, lymphedema prevalence for patients in the present study was 10% after complete level I-III axillary dissection for melanoma and 53% after additional axillary radiotherapy. Radiotherapy and wound complications were independent risk factors for the development of lymphedema. Conclusions: A suggested objective definition for arm lymphedema after axillary dissection is an arm volume increase of greater than 16% of the volume of the control arm.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B01</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B12B04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Complet</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Complete</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Completo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Ganglion axillaire</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Axillary ganglion</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Ganglio axilar</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Mélanome malin</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Malignant melanoma</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Melanoma maligno</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Dissection</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dissection</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Disección</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Définition</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Definition</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Definición</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Médecine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Medicine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Medicina</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Chirurgie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Surgery</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cirugía</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Traitement</s0>
<s5>25</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Treatment</s0>
<s5>25</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>25</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Lymphatique pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>39</s5>
</fC07>
<fN21><s1>341</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0591759 INIST</NO>
<ET>Lymphedema after complete axillary node dissection for melanoma: Assessment using a new, objective definition</ET>
<AU>STARRITT (Emma C.); JOSEPH (David); MCKINNON (J. Gregory); SING KAI LO; DE WILT (Johannes H. W.); THOMPSON (John F.)</AU>
<AF>Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital/Camperdown/Australie (1 aut., 2 aut., 3 aut., 5 aut., 6 aut.); Institute for International Health, University of Sydney/Newtown/Australie (4 aut.); TDepartment of Surgery, University of Sydney/Australie (6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Annals of surgery; ISSN 0003-4932; Coden ANSUA5; Etats-Unis; Da. 2004; Vol. 240; No. 5; Pp. 866-874; Bibl. 25 ref.</SO>
<LA>Anglais</LA>
<EA>Objectives: The objectives of this study were to define appropriate criteria for assessing the presence of lymphedema, and to report the prevalence and risk factors for development of upper limb lymphedema after level I-III axillary dissection for melanoma. Background Data: The lack of a consistent and reliable objective definition for lymphedema remains a significant barrier to appreciating its prevalence after axillary dissection for melanoma (or breast carcinoma). Methods: Lymphedema was assessed in 107 patients (82 male, 25 female) who had previously undergone complete level I-III axillary dissection. Of the 107 patients, 17 had also received postoperative axillary radiotherapy. Arm volume was measured using a water displacement technique. Change in volume of the arm on the side of the dissection was referenced to the volume of the other (control) arm. Volume measurements were corrected for the effect of handedness using corrections derived from a control group. Classification and regression tree (CART) analysis was used to determine a threshold fractional arm volume increase above which volume changes were considered to indicate lymphedema. Results: Based on the CART analysis results, lymphedema was defined as an increase in arm volume greater than 16% of the volume of the control arm. Using this definition, lymphedema prevalence for patients in the present study was 10% after complete level I-III axillary dissection for melanoma and 53% after additional axillary radiotherapy. Radiotherapy and wound complications were independent risk factors for the development of lymphedema. Conclusions: A suggested objective definition for arm lymphedema after axillary dissection is an arm volume increase of greater than 16% of the volume of the control arm.</EA>
<CC>002B01; 002B12B04</CC>
<FD>Lymphoedème; Complet; Ganglion axillaire; Mélanome malin; Dissection; Définition; Médecine; Chirurgie; Traitement</FD>
<FG>Appareil circulatoire pathologie; Lymphatique pathologie; Tumeur maligne</FG>
<ED>Lymphedema; Complete; Axillary ganglion; Malignant melanoma; Dissection; Definition; Medicine; Surgery; Treatment</ED>
<EG>Cardiovascular disease; Lymphatic vessel disease; Malignant tumor</EG>
<SD>Linfedema; Completo; Ganglio axilar; Melanoma maligno; Disección; Definición; Medicina; Cirugía; Tratamiento</SD>
<LO>INIST-2016.354000120551830190</LO>
<ID>04-0591759</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000618 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000618 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:04-0591759
   |texte=   Lymphedema after complete axillary node dissection for melanoma: Assessment using a new, objective definition
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Lymphedema after complete axillary node dissection for melanoma: Assessment using a new, objective definition

Lymphedema after complete axillary node dissection for melanoma: Assessment using a new, objective definition

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri